|Biotech Due Diligence
What a 12 months it has been for Infinity Pharma (NASDAQ: INFI), with the stock rising more than six-fold from it's low following the failure of the saridegib pancreatic cancer trial. Since then, all eyes have focused on INIF's PI3K delta/gamma inhibitor IPI-145, in development for hematological malignancies and inflammatory diseases. I have assembled some selected slides from the company's JP Morgan presentation as well as added my own notes from the webcast. Continue reading here for the annotated Infinity Pharma IPI-145 notes.